FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2551943228> ?p ?o ?g. }

• W2551943228 abstract "Background At present, in 30–35% systemic lupus erythematosus (SLE) patients antiphospholipid antibodies (aPL) are associated with the development of secondary antiphospholipid syndrome (APS), including venous and/or arterial thrombosis and other systemic disorders. Practitioners still face certain difficulties in differential diagnosis of the APS positive SLE and are in need for efficient tests to verify the diagnosis. Hp (haptoglobin) is a hemoglobin-binding glycoprotein of α2-globulin serum proteins fraction induced by seromucoids at the early stages of an inflammatory process. There are three phenotypic variants of Hp: Hp 1–1, Hp 2–1 and Hp 2–2. The practical value of Hp test in SLE patients is the possibility to diagnose a genetic predisposition to APS to predict severity of the disease. Objectives Determine the carriage frequency of different Hp phenotypes in SLE patients with APS, and reveal a correlation between the level of serum Hp and clinical manifestations of APS in SLE patients. Methods The study is based on the follow-up results of 103 SLE patients under treatment at the Republican Centre of Rheumatology, Tashkent Medical Academy. Entry criteria of patients in the study: reliable diagnosis of SLE, verified in accordance with SLICC (2012) criteria and the informed consent to participation. The secondary APS (SAPS) was based on the Sydney (2006) Classification Criteria for APS. Haptoglobin test was performed using disc polyacrylamide gel electrophoresis (PAGE). Results We have defined APS in 44 of 103 (42.7%) SLE patients. In 29 of 44 (65%) cases the APS diagnosis was based on major manifestations, and in 15 of 44 (35%) – by the presence of two or more additional signs. Distribution of SLE patients with APS, depending on the Hp phenotype: 38 (86.4%) patients with APS had Hp 1–1, 6 (13.6%) – Hp 2–1, 0 (0%) - Hp 2–2 phenotype (P Conclusions Results of our investigation showed that development of SLE and APS is characteristic for Hp 1–1 phenotype, apparently, being a predisposing factor to the autosensitisation and a genetic marker for APS. Furthermore, there is an expressed correlation between Hp level and clinical manifestations of APS. References Reshetnyak TM. Antiphospholipid syndrome: state of the art and future tasks. J Nauchno-prakticheskaya revmatologiya. 2013. 11–14:51–1. Erkan D, Aguiar CL, Andrade D, Cohen H, Cuadrado MJ, Danowski A. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014 13(6):685–96. Disclosure of Interest None declared" @default.
• W2551943228 created "2016-11-30" @default.
• W2551943228 creator A5066730272 @default.
• W2551943228 creator A5078218343 @default.
• W2551943228 date "2016-06-01" @default.
• W2551943228 modified "2023-09-28" @default.
• W2551943228 title "AB0430 Carriage Frequency of Haptoglobin Phenotypes in Systemic Lupus Erythematosus Patients with Antiphospholipid Syndrome and Their Association with Clinical Manifestations" @default.
• W2551943228 doi "https://doi.org/10.1136/annrheumdis-2016-eular.5317" @default.
• W2551943228 hasPublicationYear "2016" @default.
• W2551943228 type Work @default.
• W2551943228 sameAs 2551943228 @default.
• W2551943228 citedByCount "0" @default.
• W2551943228 crossrefType "journal-article" @default.
• W2551943228 hasAuthorship W2551943228A5066730272 @default.
• W2551943228 hasAuthorship W2551943228A5078218343 @default.
• W2551943228 hasConcept C126322002 @default.
• W2551943228 hasConcept C198451711 @default.
• W2551943228 hasConcept C203014093 @default.
• W2551943228 hasConcept C206396517 @default.
• W2551943228 hasConcept C2776874634 @default.
• W2551943228 hasConcept C2776912625 @default.
• W2551943228 hasConcept C2779134260 @default.
• W2551943228 hasConcept C2780868729 @default.
• W2551943228 hasConcept C71924100 @default.
• W2551943228 hasConcept C90924648 @default.
• W2551943228 hasConceptScore W2551943228C126322002 @default.
• W2551943228 hasConceptScore W2551943228C198451711 @default.
• W2551943228 hasConceptScore W2551943228C203014093 @default.
• W2551943228 hasConceptScore W2551943228C206396517 @default.
• W2551943228 hasConceptScore W2551943228C2776874634 @default.
• W2551943228 hasConceptScore W2551943228C2776912625 @default.
• W2551943228 hasConceptScore W2551943228C2779134260 @default.
• W2551943228 hasConceptScore W2551943228C2780868729 @default.
• W2551943228 hasConceptScore W2551943228C71924100 @default.
• W2551943228 hasConceptScore W2551943228C90924648 @default.
• W2551943228 hasLocation W25519432281 @default.
• W2551943228 hasOpenAccess W2551943228 @default.
• W2551943228 hasPrimaryLocation W25519432281 @default.
• W2551943228 hasRelatedWork W1973706980 @default.
• W2551943228 hasRelatedWork W2015878170 @default.
• W2551943228 hasRelatedWork W2030402915 @default.
• W2551943228 hasRelatedWork W2061394912 @default.
• W2551943228 hasRelatedWork W2063012843 @default.
• W2551943228 hasRelatedWork W2064687788 @default.
• W2551943228 hasRelatedWork W2066095755 @default.
• W2551943228 hasRelatedWork W2341824054 @default.
• W2551943228 hasRelatedWork W2471124590 @default.
• W2551943228 hasRelatedWork W2551780948 @default.
• W2551943228 hasRelatedWork W2566526992 @default.
• W2551943228 hasRelatedWork W2752622099 @default.
• W2551943228 hasRelatedWork W2887943084 @default.
• W2551943228 hasRelatedWork W2901224150 @default.
• W2551943228 hasRelatedWork W2910225408 @default.
• W2551943228 hasRelatedWork W2938696124 @default.
• W2551943228 hasRelatedWork W3045034414 @default.
• W2551943228 hasRelatedWork W3081216030 @default.
• W2551943228 hasRelatedWork W3090943491 @default.
• W2551943228 hasRelatedWork W3206375300 @default.
• W2551943228 isParatext "false" @default.
• W2551943228 isRetracted "false" @default.
• W2551943228 magId "2551943228" @default.
• W2551943228 workType "article" @default.